Search
Research
Limited impact of neonatal or early infant schedules of 7-valent pneumococcal conjugate vaccinationEarly 7vPCV schedules have limited impact on pneumococcal vaccine type carriage in PNG
Research
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 yearsIn women older than 25 years, the HPV 16/18 vaccine continues to protect against infections, cytological abnormalities, and lesions associated with HPV 16/18
Research
Australia-wide point prevalence survey of antimicrobial prescribing in neonatal units: How much and how good?This is the first Australia-wide point prevalence survey of neonatal antimicrobial prescribing in tertiary children's hospitals.
Research
Group a streptococcal carriage and seroepidemiology in children up to 10 years of age in Australia.This study aimed to acquire nationally representative epidemiological data on GAS in Australia to scope the appropriate age for vaccination with a potential...
Research
Febrile seizures following measles and varicella vaccines in young children in AustraliaFebrile seizures (FS) are common in childhood with incidence peaking in the second year of life when measles and varicella-containing vaccines are administered.
Research
Natural history of progression of HPV infection to cervical lesion or clearance: Analysis of the control arm of the large, randomised PATRICIA studyThe control arm of PATRICIA (PApillomaTRIal against Cancer In young Adults, NCT00122681) was used to investigate the risk of progression from cervical HPV...
Research
Predictors of Disease Severity in Children Hospitalized for Pertussis during an EpidemicThis study aimed to determine factors associated with severe pertussis in hospitalized children during an epidemic using a novel pertussis severity scoring...
Research
Pandemic clinical case definitions are non-specificDuring the early phases of the 2009 pandemic, subjects with influenza-like illness only had laboratory testing specific for the new A(H1N1)pdm09 virus.
Research
Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody responseSARS-CoV-2 nucleocapsid (N) protein antibodies can be used to identify the serological response to natural infection in those who have previously received a COVID-19 spike-based vaccine. Anti-N antibody responses can also be induced by inactivated whole SARS-CoV-2 virus vaccines, such as CoronaVac. We aimed to characterise antibody responses to the N protein following COVID-19 and following vaccination with CoronaVac.
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.